Clear Solutions Biotech Joins Forces with Lab Sophia for HA-Based Drug Development

Clear Solutions Biotech, Inc. (CSBI; Stony Brook, NY) and Laboratorios Sophia (Guadalajara, Mexico) have signed an agreement to pursue development of hyaluronic acid-based drugs for a variety of ophthalmic indications. Lab Sophia has embarked on a program to extend its drug pipeline into sustained release ophthalmic drugs with new properties, and is building a new manufacturing facility in Mexico to manufacture for the U.S. market.

Clear Solutions Biotech's technology platform focuses on the covalent modification and/or derivatization of hyaluronic acid to allow sustained delivery of therapeutic agents. The company's technology has been applied to tissue engineering, drug delivery and biomaterials applications. CSBI has also developed conjugates of cytotoxic, anti-inflammatory and steroidal drugs that are currently being evaluated in pre-clinical studies.

Edited by Beth Brindle

For more information: Philip Dehazya, Ph.D., Director, Technology Development, Clear Solutions Biotech, Inc. Tel: 516-689-9036; Fax: 516-689-6880.